Hookipa Pharma, a Phase 2 biotech developing T cell immunotherapies for various cancers, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The New York, NY-based company was founded in 2011 and booked $8 million in sales for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol HOOK. Hookipa Pharma filed confidentially on December 14, 2018. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
